Pregabalin in patients with antidepressant treatment-resistant somatoform disorders: A case series [17]

Journal of Clinical Psychopharmacology

Volumn 27, Issue 5, 2007, Pages 537-539

  Harnack, Daniel ^a   Scheel, Michael ^a   Mundt, Adrian ^a   Kupsch, Andreas ^a   Heinz, Andreas ^a   Ströhle, Andreas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; DULOXETINE; FLUOXETINE; MIRTAZAPINE; PREGABALIN; PROMETHAZINE; QUETIAPINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRIMIPRAMINE; VENLAFAXINE;

ADULT; CLINICAL ARTICLE; COGNITIVE THERAPY; COMORBIDITY; CONTROLLED STUDY; DIZZINESS; FATIGUE; FEMALE; GAIT DISORDER; HUMAN; LETTER; MALE; MENTAL DISEASE; PRIORITY JOURNAL; SCORING SYSTEM; SOMATOFORM DISORDER; TREATMENT RESPONSE;

ADULT; ANALGESICS; ANTIDEPRESSIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; SOMATOFORM DISORDERS; TREATMENT OUTCOME;

EID: 34548702441     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31814e5e84     Document Type: Letter

References (13)

1. Barsky AJ, Orav EJ, Bates DW. Somatization increases medical utilization and costs independent of psychiatric and medical comorbidity. Arch Gen Psychiatry. 2005;62:903-910.
2. Creed F, Barsky A. A systematic review of the epidemiology of somatisation disorder and hypochondriasis. J Psychosom Res. 2004;56: 391-408.
3. Janca A. Rethinking somatoform disorders. Curr Opin Psychiatry. 2005;18:65-71.
4. Volz HP, Stieglitz RD, Menges K, et al. Somatoform disorders - diagnostic concept, controlled clinical trials, and methodological issues. Pharmacopsychiatry. 1994;27:231-237.
5. Jackson JL, O'Malley PG, Kroenke K. Antidepressants and cognitive-behavioral therapy for symptom syndromes. CNS Spectr. 2006; 11:212-222.
6. Stahl SM. Anticonvulsants as anxiolytics, part 2: pregabalin and gabapentin as alpha(2)-delta ligands at voltage-gated calcium channels. J Clin Psychiatry. 2004;65:460-461.
7. Garcia-Campayo J, Sanz-Carrillo C. Gabapentin for the treatment of patients with somatization disorder. J Clin Psychiatry. 2001; 62:474.
8. McIntyre RS, Konarski JZ, Mancini DA, et al. Improving outcomes in depression: a focus on somatic symptoms. J Psychosom Res. 2006; 60:279-282.
9. Farabaugh A, Mischoulon D, Fava M, et al. The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients. Int Clin Psychopharmacol. 2005;20: 87-91.
10. Dooley DJ, Taylor CP, Donevan S, et al. Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol Sci. 2007;28:75-82.
11. Chesler EJ, Ritchie J, Kokayeff A, et al. Genotype-dependence of gabapentin and pregabalin sensitivity: the pharmacogenetic mediation of analgesia is specific to the type of pain being inhibited. Pain. 2003;106: 325-335.
12. Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:1264-1273.
13. Wedekind D, Bandelow B, Fentzahn E, et al. The quantification inventory for somatoform syndromes (QUISS): a novel instrument for the assessment of severity. Eur Arch Psychiatry Clin Neurosci. 2007;257:153-163.